Better Health, Brighter Future

Takeda R&D

Tadataka Yamada
Chief Medical & Scientific Officer

May 15, 2015

Takeda Pharmaceutical Company Limited

Important notice

Forward-Looking Statements

This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future.

All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.

Medical Information

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drug including the ones under development.

Increasingly focused, innovative and global portfolio

Global products

New and Potential Product Approvals	Oncology	CNS	CVM	GI	Vaccine	Other TA
FY2008 - 2012	ADCETRIS® VECTIBIX®	REMINYL®	NESINA® AZILVA® EDARBI® LOTRIGA®	DEXILANT®		COLCRYS® ULORIC® ALVESCO® DAXAS®
FY2013 - 2017	ixazomib	BRINTELLIX® glatiramer (COPAXONE®*)	CONTRAVE® ZAFATEK®	ENTYVIO® TAKECAB®	TAK-850 Influenza	
FY2018 - 2022	MLN0264 TAK-385 MLN0128 alisertib	AD-4833/ TOMM40 rasagiline (AZILECT®*)	TAK-272	TAK-114	TAK-003 Dengue TAK-214 Norovirus	namilumab

Note: Assets shown are in Phase 2 or later and have the most substantial financial expectations

CNS: Central Nervous System; CVM: Cardiovascular & Metabolic; GI: Gastroenterology; TA: Therapeutic Area
*Overseas brand names. Brand names in Japan are not decided.

ENTYVIO®: Addressing unmet medical need of patients with inflammatory bowel disease

- ***First and only*** biologic engineered for the treatment of moderately to severely active ulcerative colitis and Crohn's disease
- ***First and only*** product in the US and Europe indicated for both anti-TNFα -naïve and anti-TNFα-failure patients, both in UC and CD
- ***First and only*** biologic with a specific binding action designed for a gut-homing inflammatory pathway
- ***First and only*** simultaneous launch in both UC and CD in US and Europe
- No boxed warning in label

ENTYVIO®: Building on its rapid uptake, Takeda has an ambitious life-cycle management program



* Investigator Initiated Sponsored Research

All plans subject to regulatory feedback and evolving marketplace dynamics

Ixazomib program designed to demonstrate sustained proteasome inhibition is best way to treat multiple myeloma



***Revlimid® (lenalidomide) + dexamethasone**

By improving both safety and simplicity, we aspire to deliver longer treatment and deeper efficacy

Single Agent Ixazomib: Longer treatment gives stronger response
Best response in patients receiving maintenance (n=21/50)



Kumar, ASH 2014
Oral Abstract #82

- Data demonstrated acceptable tolerability with no discontinuations due to AEs and no on-study deaths during maintenance phase
- Drug-related grade 3 adverse events were reported in 14 percent of patients during ixazomib maintenance therapy

Takeda

Takeda Pharmaceutical Company Limited